International Journal of Hematology

DOI: 10.1007/s12185-018-2519-y Pages: 365-370

Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence

1. National Cancer Center Hospital East, Department of Hematology

2. Gifu University, United Graduate School of Drug Discovery and Medical Information Sciences

Correspondence to:
Yosuke Minami
Tel: +81-4-7133-1111



Chronic myeloid leukemia (CML) is effectively treated with tyrosine kinase inhibitors (TKI) targeted against BCR-ABL. We previously reported the investigation of residual CML diseases during TKI treatment using FACS-sorting and quantitative RT-PCR of BCR-ABL among each population; total mononuclear cells, hematopoietic stem cells, and myeloid progenitors. The observations also implied that the second-generation of ABL-tyrosine kinase inhibitors (2nd TKIs), dasatinib or nilotinib therapy can be more promising approach for efficient reduction of the CML stem cells. Moreover, we need to develop the evaluation method of the residual CML diseases to establish rational therapy-cessation strategies in CML.

This article is freely available, click here to access the full text/PDF

Share the Knowledge